SILVERARC CAPITAL MANAGEMENT LLC's Q2 2022 13F: 13 new positions, 19 exits
Form 13F-HR for the quarter ended Jun 30, 2022 · filed Jul 25, 2022 · 59 reported positions · accession 0001420506-22-001285
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| Exited | ATHIRA PHARMA INC (ATHA) | 12.8% | — | −12.8 pts | −10,000 sh | −100% |
| Exited | SIERRA ONCOLOGY INC (SRRA) | 6.7% | — | −6.7 pts | −443K sh | −100% |
| Reduced | BIOHAVEN PHARMACTL HLDG CO L (BHVN) | 2.1% | 1.8% | −0.3 pts | −76,123 sh | −74% |
| Increased | MORPHIC HLDG INC (MORF) | 1.3% | 4.3% | +3.0 pts | +350K sh | +509% |
| Increased | VERACYTE INC (VCYT) | 5.6% | 6.7% | +1.1 pts | +293K sh | +69% |
| Increased | SEAGEN INC (SGEN) | 0.7% | 3.4% | +2.6 pts | +29,831 sh | +272% |
| Reduced | CTI BIOPHARMA CORP (CTIC) | 5.0% | 3.9% | −1.1 pts | −870K sh | −39% |
| New | ORIC PHARMACEUTICALS INC (ORIC) | — | 2.3% | +2.3 pts | +1.08M sh | new |
| Exited | ITEOS THERAPEUTICS INC (ITOS) | 2.1% | — | −2.1 pts | −139K sh | −100% |
| Increased | XENON PHARMACEUTICALS INC (XENE) | 0.7% | 3.3% | +2.6 pts | +132K sh | +130% |
| New | MERSANA THERAPEUTICS INC (MRSN) | — | 1.8% | +1.8 pts | +850K sh | new |
| Increased | KRYSTAL BIOTECH INC (KRYS) | 1.5% | 3.2% | +1.8 pts | +58,788 sh | +126% |
| Increased | ACLARIS THERAPEUTICS INC (ACRS) | 2.2% | 3.5% | +1.3 pts | +264K sh | +96% |
| Increased | CERUS CORP (CERS) | 3.6% | 5.2% | +1.6 pts | +695K sh | +50% |
| Increased | MERUS N V (MRUS) | 4.1% | 5.0% | +0.9 pts | +144K sh | +44% |
| Increased | BELLUS HEALTH INC NEW (BLU) | 0.1% | 6.8% | +6.7 pts | +327K sh | +26% |
| New | CULLINAN ONCOLOGY INC (CGEM) | — | 1.3% | +1.3 pts | +213K sh | new |
| New | REGENXBIO INC (RGNX) | — | 1.2% | +1.2 pts | +104K sh | new |
| Exited | GALAPAGOS NV (LKFT) | 1.2% | — | −1.2 pts | −41,002 sh | −100% |
| New | AKERO THERAPEUTICS INC (AKRO) | — | 1.2% | +1.2 pts | +260K sh | new |
| Exited | VIRIDIAN THERAPEUTICS INC (VRDN) | 1.1% | — | −1.1 pts | −126K sh | −100% |
| Increased | COGENT BIOSCIENCES INC (COGT) | 2.0% | 3.5% | +1.4 pts | +247K sh | +43% |
| Increased | INSMED INC (INSM) | 1.1% | 2.0% | +0.8 pts | +110K sh | +108% |
| Increased | BIOGEN INC (BIIB) | 0.1% | 2.0% | +1.9 pts | +10,577 sh | +103% |
| New | PHREESIA INC (PHR) | — | 0.9% | +0.9 pts | +78,111 sh | new |
| Exited | NEUROCRINE BIOSCIENCES INC (NBIX) | 0.9% | — | −0.9 pts | −20,482 sh | −100% |
| New | DAY ONE BIOPHARMACEUTICALS I (DAWN) | — | 0.9% | +0.9 pts | +105K sh | new |
| Increased | ELIEM THERAPEUTICS INC (ELYM) | 0.4% | 1.0% | +0.7 pts | +625K sh | +708% |
| Exited | LEAP THERAPEUTICS INC (LPTX) | 0.9% | — | −0.9 pts | −1.03M sh | −100% |
| New | CVRX INC (CVRX) | — | 0.8% | +0.8 pts | +292K sh | new |
| Exited | JOUNCE THERAPEUTICS INC (JNCE) | 0.8% | — | −0.8 pts | −248K sh | −100% |
| Exited | POINT BIOPHARMA GLOBAL INC (PNT) | 0.8% | — | −0.8 pts | −205K sh | −100% |
| Exited | ASLAN PHARMACEUTICALS LTD (ASLN) | 0.8% | — | −0.8 pts | −500K sh | −100% |
| Exited | ASCENDIS PHARMA A/S (ASND) | 0.7% | — | −0.7 pts | −25,000 sh | −100% |
| Reduced | NGM BIOPHARMACEUTICALS INC (NGM) | 1.4% | 0.5% | −0.9 pts | −112K sh | −56% |
| Exited | CYCLACEL PHARMACEUTICALS INC (CYCC) | 0.7% | — | −0.7 pts | −463K sh | −100% |
| New | NKARTA INC (NKTX) | — | 0.6% | +0.6 pts | +111K sh | new |
| Exited | MEDICUS SCIENCES ACQUISITION (MSAC) | 0.6% | — | −0.6 pts | −131K sh | −100% |
| Exited | LUCIRA HEALTH INC (LHDXQ) | 0.5% | — | −0.5 pts | −311K sh | −100% |
| Increased | APELLIS PHARMACEUTICALS INC (APLS) | 2.5% | 2.8% | +0.2 pts | +24,427 sh | +23% |
| New | ZYMEWORKS INC | — | 0.5% | +0.5 pts | +208K sh | new |
| Reduced | IMMUNOGEN INC (IMGN) | 1.5% | 0.9% | −0.6 pts | −229K sh | −35% |
| Exited | NEXTCURE INC (NXTC) | 0.5% | — | −0.5 pts | −196K sh | −100% |
| New | SILVERBACK THERAPEUTICS INC (SPRY) | — | 0.4% | +0.4 pts | +209K sh | new |
| Increased | VIEWRAY INC (VRAYQ) | 0.8% | 0.9% | +0.1 pts | +297K sh | +68% |
| Reduced | IMMATICS N.V (IMTX) | 1.7% | 1.4% | −0.2 pts | −90,231 sh | −20% |
| Increased | VERTEX PHARMACEUTICALS INC (VRTX) | 0.9% | 1.4% | +0.4 pts | +2,776 sh | +36% |
| Exited | IMMUNIC INC (IMUX) | 0.4% | — | −0.4 pts | −68,475 sh | −100% |
| Reduced | MIRATI THERAPEUTICS INC (MRTX) | 1.8% | 1.1% | −0.6 pts | −9,719 sh | −21% |
| New | CHEMOCENTRYX INC (CCXI) | — | 0.3% | +0.3 pts | +26,036 sh | new |
The 50 largest of 76 changes, by size of the trade. Full holdings for this quarter.
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 50.5% of the equity book
Changes in the top 10 this quarter: BLU entered · MORF entered · ACRS entered · COGT entered · SGEN entered · ATHA left · SRRA left · HZNP left · APEN left · APLS left
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | INTRA-CELLULAR THERAPIES INC (ITCI) | 8.9% | 8.4% | |
| 2 | BELLUS HEALTH INC NEW (BLU) | 0.1% | 6.8% | Entered the top 10 |
| 3 | VERACYTE INC (VCYT) | 5.6% | 6.7% | |
| 4 | CERUS CORP (CERS) | 3.6% | 5.2% | |
| 5 | MERUS N V (MRUS) | 4.1% | 5.0% | |
| 6 | MORPHIC HLDG INC (MORF) | 1.3% | 4.3% | Entered the top 10 |
| 7 | CTI BIOPHARMA CORP (CTIC) | 5.0% | 3.9% | |
| 8 | ACLARIS THERAPEUTICS INC (ACRS) | 2.2% | 3.5% | Entered the top 10 |
| 9 | COGENT BIOSCIENCES INC (COGT) | 2.0% | 3.5% | Entered the top 10 |
| 10 | SEAGEN INC (SGEN) | 0.7% | 3.4% | Entered the top 10 |
| — | ATHIRA PHARMA INC (ATHA) | 12.8% | 0.0% | Left the top 10 |
| — | SIERRA ONCOLOGY INC (SRRA) | 6.7% | 0.0% | Left the top 10 |
| — | HORIZON THERAPEUTICS PUB L (HZNP) | 3.4% | 2.7% | Left the top 10 |
| — | APOLLO ENDOSURGERY INC (APEN) | 2.9% | 1.8% | Left the top 10 |
| — | APELLIS PHARMACEUTICALS INC (APLS) | 2.5% | 2.8% | Left the top 10 |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).
Option positions (puts and calls)
Reported separately from the positions above. The value a 13F reports for an option is that of the underlying shares, not the option itself.
| Activity | Security | Type | Shares before | Shares now | Reported value |
|---|---|---|---|---|---|
| New | INVESCO QQQ TR (QQQ) | Put | 0 | 163K | $45.5M |
| Reduced | SPDR SER TR (XBI) | Call | 300K | 208K | $15.5M |
| New | ANAVEX LIFE SCIENCES CORP (AVXL) | Put | 0 | 917K | $9.18M |
| New | VERU INC (VERU) | Put | 0 | 780K | $8.82M |
| New | PROMETHEUS BIOSCIENCES INC (RXDX) | Put | 0 | 302K | $8.52M |
| New | MIRATI THERAPEUTICS INC (MRTX) | Call | 0 | 101K | $6.77M |
| New | ALNYLAM PHARMACEUTICALS INC (ALNY) | Call | 0 | 40,000 | $5.83M |
| New | CONTRAFECT CORP (CFRX) | Put | 0 | 1.56M | $4.8M |
| Increased | IVERIC BIO INC (ISEE) | Put | 94,600 | 431K | $4.15M |
| Exited | IMMUNOGEN INC (IMGN) | Call | 300K | 0 | $0 |
| New | HUMANIGEN INC (HGENQ) | Put | 0 | 781K | $1.38M |
| New | CELLDEX THERAPEUTICS INC NEW (CLDX) | Put | 0 | 36,000 | $971K |
| Exited | APTINYX INC (APTX) | Put | 202K | 0 | $0 |